MCL1 and breast carcinoma: Immunoprecipitation analysis confirmed that the decline in Mcl-1 (Figure 2B, left panel) and Bcl-2 (data not shown) was only in CHX-treated normal mammary epithelial cells but not in the CHX-treated breast cancer cells (Figure 2B, right panel).